MARKET

XXII

XXII

22ND CENTURY
AMEX

Real-time Quotes | Nasdaq Last Sale

2.690
-0.120
-4.27%
After Hours: 2.680 -0.01 -0.37% 19:52 01/26 EST
OPEN
2.760
PREV CLOSE
2.810
HIGH
2.770
LOW
2.630
VOLUME
1.89M
TURNOVER
--
52 WEEK HIGH
3.130
52 WEEK LOW
0.5500
MARKET CAP
373.53M
P/E (TTM)
-18.6806
1D
5D
1M
3M
1Y
5Y
News
Financial
Releases
Corp Actions
Analysis
Profile
The Buffalo News Op-ed: 22nd Century CEO Urges FDA to Proceed with Plan to Limit Nicotine Levels in Cigarettes
The FDA Can Save 8 Million Lives and Prevent 1,600 Kids From Becoming Addicted Every DayWILLIAMSVILLE, N.Y., Jan. 26, 2021 (GLOBE NEWSWIRE) -- 22nd Century Group, Inc., a leading plant-based, biotechnology company that is focused on tobacco harm reduction,...
GlobeNewswire · 13h ago
22nd Century Group Expands VLN® Tobacco Growing Program to Support Anticipated Demand of the Companys Reduced Nicotine Content Cigarettes
Company will significantly increase planting in the 2021 crop yearWILLIAMSVILLE, N.Y., Jan. 12, 2021 (GLOBE NEWSWIRE) -- 22nd Century Group, Inc. (NYSE American: XXII), a leading plant-based, biotechnology company that is focused on tobacco harm reduction,...
GlobeNewswire · 01/13 04:00
22nd Century Group Prepared To Launch VLK Cigarettes Within 90 Days After Receiving Marketing Authorization From FDA
-Reuters
Reuters · 01/11 17:03
22nd Century Group Expands VLN(R) Tobacco Growing Program to Support Anticipated Demand of the Company's Reduced Nicotine Content Cigarettes
22nd Century Group, Inc. (NYSE American: XXII), a leading plant-based, biotechnology company that is focused on tobacco harm reduction, very low nicotine content tobacco, and hemp/cannabis research, announced today that the Company will significantly expan...
GlobeNewswire · 01/11 17:00
22nd Century Group Expands VLN® Tobacco Growing Program to Support Anticipated Demand of the Companys Reduced Nicotine Content Cigarettes
Company will significantly increase planting in the 2021 crop yearWILLIAMSVILLE, N.Y., Jan. 11, 2021 (GLOBE NEWSWIRE) -- 22nd Century Group, Inc. (NYSE American: XXII), a leading plant-based, biotechnology company that is focused on tobacco harm reduction,...
GlobeNewswire · 01/11 17:00
Did Business Growth Power 22nd Century Group's (NYSEMKT:XXII) Share Price Gain of 116%?
Unfortunately, investing is risky - companies can and do go bankrupt. On the other hand, if you find a high quality...
Simply Wall St. · 12/23/2020 09:49
22nd Century Group Achieves Breakthrough Hemp/Cannabis GMO Technology; Granted New Patent for Controlling Genes Responsible for Production of CBD, THC, and Other Valuable Cannabinoids
22nd Century Group, Inc. (NYSE American: XXII), a leading plant-based, biotechnology company focused on tobacco harm reduction, very low nicotine content tobacco, and hemp/cannabis research, announced today that it was granted a new U.S. patent related to ...
GlobeNewswire · 12/17/2020 15:10
22nd Century Group Achieves Breakthrough Hemp/Cannabis GMO Technology; Granted New Patent for Controlling Genes Responsible for Production of CBD, THC, and Other Valuable Cannabinoids
New intellectual property facilitates the precise control and modulation of cannabinoid productionWILLIAMSVILLE, N.Y., Dec. 17, 2020 (GLOBE NEWSWIRE) -- 22nd Century Group, Inc. (NYSE American: XXII), a leading plant-based, biotechnology company focused on...
GlobeNewswire · 12/17/2020 15:10
More
Forecast
EPSBVPSCFPS
Actual (USD)
Estimate (USD)
Income StatementMore
Net IncomeTotal RevenueOperating Income
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
OperatingInvestingFinancing
Operating (USD)
YoY (%)
Learn about the latest financial forecast of XXII. Analyze the recent business situations of 22ND CENTURY through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 1 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average XXII stock price target is 4.000 with a high estimate of 4.000 and a low estimate of 4.000.
EPS
Institutional Holdings
Institutions: 110
Institutional Holdings: 35.63M
% Owned: 25.66%
Shares Outstanding: 138.86M
TypeInstitutionsShares
Increased
26
1.15M
New
10
11.16M
Decreased
24
726.16K
Sold Out
14
345.75K
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Environmental Services & Equipment
-1.03%
Professional & Commercial Services
-0.45%
Key Executives
Chairman/Director
Nora Sullivan
President/Chief Operating Officer
Michael Zercher
Chief Executive Officer
James Mish
Chief Financial Officer
John Franzino
Vice President
John Brodfuehrer
Vice President
Lisa Parks
Vice President - Research & Development
Juan Tamburrino
Director of Investor Relations
Mei Kuo
Independent Director
Michael Koganov
Independent Director
Roger O'Brien
Independent Director
Richard Sanders
  • Dividends
  • Splits
  • Insider Activity
No Data
About XXII
22nd Century Group, Inc. is a plant biotechnology company. The Company is focused on technology that allows increasing or decreasing the level of nicotine and other nicotinic alkaloids in tobacco plants, and levels of cannabinoids in cannabis plants through genetic engineering and plant breeding. It is engaged in various activities, including research and development of less harmful or modified risk tobacco products and tobacco plant varieties; development of X-22, a smoking cessation aid consisting of very low nicotine (VLN) cigarettes; manufacture, marketing and distribution of its RED SUN and MAGIC cigarettes; production of SPECTRUM research cigarettes for the National Institute on Drug Abuse (NIDA); contract manufacturing of third-party branded tobacco products, and research and development of plant varieties of hemp/cannabis, such as plants with low to no amounts of delta-9-tetrahydrocannabinol (THC), plants with high levels of cannabidiol (CBD), and other non-THC cannabinoids.

Webull offers kinds of 22nd Century Group Inc stock information, including AMEX:XXII real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, XXII stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading XXII stock methods without spending real money on the virtual paper trading platform.